Agios Pharmaceuticals
AGIO
198 hedge funds and large institutions have $3.3B invested in Agios Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 92 increasing their positions, 44 reducing their positions, and 28 closing their positions.
109% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 44
64% more capital invested
Capital invested by funds: $2.01B → $3.3B (+$1.29B)
50% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 28
5% more funds holding
Funds holding: 189 → 198 (+9)
2.51% less ownership
Funds ownership: 105.35% → 102.84% (-2.5%)
14% less call options, than puts
Call options by funds: $26M | Put options by funds: $30.4M
Top Buyers
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$47.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$47.2M |
| 3 |
Goldman Sachs
New York
|
+$38.3M |
| 4 |
BlackRock
New York
|
+$37.1M |
| 5 |
PA
Perceptive Advisors
New York
|
+$34M |
Top Sellers
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$40.9M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$13.6M |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
-$13.6M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$12.6M |
| 5 |
CII
Capital International Inc
Los Angeles,
California
|
-$11.4M |
AGIO Hedge Fund Activity: Q4 2019 in Review
198 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2019, worth a combined $3.3B — up 64% from $2.01B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new AGIO positions and 28 closed out — a net gain of 14 holders — while 92 added to existing stakes and 44 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $47.2M. The largest seller was Baillie Gifford & Co, cutting an estimated $40.9M.
- 198 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2019, up from 189 in Q3 2019.
- Funds reported $3.3B of Agios Pharmaceuticals stock for Q4 2019, up 64% quarter-over-quarter.
- 42 funds opened new Agios Pharmaceuticals positions in Q4 2019 and 28 closed out, a net change of +14 holders.
- The largest Agios Pharmaceuticals buyer in Q4 2019 was Farallon Capital Management, an estimated $47.2M added.
- The largest Agios Pharmaceuticals seller in Q4 2019 was Baillie Gifford & Co, an estimated $40.9M sold.
Based on aggregated 13F filings for Q4 2019.